About the Landscape Review
Using data derived from Beacon Bispecific, The H1 2023 Bispecific Landscape Review provides valuable insight into the bispecific drug and trial landscape so far throughout 2023.
Download our detailed analysis of the drug and trial landscapes (as of July 14th 2023), along with a comprehensive list of H1 2023 commercial developments and regulatory announcements.
The Review covers:
- The Trial Landscape – a detailed analysis of trial developments, such as trials initiated and phase development, so far this year while providing context as to performance compared to previous years.
- The Drug Landscape – a review of new bispecific assets this year including top targets, phase distribution and therapeutic classes, as well as an analysis on CD3 and target combinations.
- Regulatory Announcements – an extensive list of every regulatory announcement so far this year, including first-time approvals, collaborations, mergers, and acquisitions.
Please note that some information has been removed from the downloadable content below. If you would like to receive the complete version and speak with one of our specialists in bispecific drugs and trials, please do not hesitate to contact email@example.com to discuss your drug development data needs.
Beacon Bispecific customers, please log in to Beacon and go to the Analysis tab to download your complete version.
How the most complete bispecific database can help you
What we cover
This database solution is manually curated by sector-specific scientists and includes clinical trial and drug records for preclinical, active, approved, and discontinued antibody-based drugs that are designed to bind to two or more target antigens. We also cover:
- Whole Antibodies
- Antibody Fragments
- Augmented Antibodies
- Bispecific Fusion Proteins
How Beacon Bispecific works
Search the clinical trial and drug landscape by multiple targets, scaffold and over 80 different bispecific formats, instantaneously and/or extract the data points you need to conduct more complex analysis.